Biodesix, Inc., today announced that it has completed acquisition of Oncimmune’s laboratory and incidental pulmonary nodule (IPN) malignancy test in the United States.
Biodesix, Inc. the leader in lung cancer diagnostics, today announced the appointment of internationally recognized lung cancer expert, James Jett, M.D., as Chief Medical Officer.
Biodesix, Inc., today announced it has been issued U.S. Patent Number 10,422,729, which covers the Biodesix Collection Device (BCD).
Biodesix Highlights Pipeline and Companion Diagnostic Development at World CDx and RAS-Targeted Drug Discovery
Biodesix highlighted their development and commercialization of companion diagnostics for directing the treatment of non-small cell lung cancer at the 2019 Clinical Biomarkers & World CDx Conference.
Biodesix Announces New Clinical Data Demonstrating VeriStrat Testing Predicts Survival in Advanced NSCLC and Immunotherapy
Biodesix, Inc. this week highlighted findings from multiple studies demonstrating the significance and clinical utility of its VeriStrat® blood-based proteomic test.
Biodesix appointed Robert W. Georgantas III, Ph.D., as the company’s Senior Vice President (SVP) of Research and Translational Science.
Biodesix announces the appointment of Charles Watts, M.D. to the company’s board of directors.
Biodesix announced that it is collaborating with immune-oncology firm Immodulon Therapeutics to identify proteomic markers linked to pancreatic cancer.
Biodesix Reaches Agreement to Deliver Next-Generation Sequencing Assay for Blood-Based Companion Diagnostic Solutions in Cancer
Biodesix has entered into an agreement with Thermo Fisher Scientific.
Biodesix will acquire Oncimmune’s laboratory and incidental pulmonary nodule malignancy test in the U.S.